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ABSTRACT
Venom phospholipases A2 (PLA2) are associated with neurotoxic, myotoxic, cardiotoxic, platelet aggregation, 
and edema activities. A PLA2 (Drs-PLA2) was purified from Daboia russelii siamensis venom by a two-step 
purification procedure consisting of size-exclusion, followed by anion exchange high performance liquid chro-
matography (HPLC). The molecular weight of the Drs-PLA2 was 13,679Da, which was determined by MALDI-
TOF mass spectrometry. Its N-terminal amino acid sequence was homologous to basic PLA2s of viperid snake 
venoms. The Drs-PLA2 had indirect hemolytic and anticoagulant activities, cytotoxic activity with a CC50 of 
65.8nM, and inhibited SK-MEL-28 cell migration with an IC50 of 25.6nM. In addition, the Drs-PLA2 inhibited 
the colonization of B16F10 cells in lungs of BALB/c mice by ∼65%.
KEYWORDS: Daboia russelii siamensis, phospholipase A2, cytotoxic, cell migration inhibition, lung tumor   colonization
INTRODUCTION
The superfamily of phospholipase A2 enzymes have been 
classified as 15 groups and many subgroups that include 
five distinct types of enzymes, namely the secreted PLA2 
(sPLA2), the cytosolic PLA2 (cPLA2), the Ca2+ independ-
ent PLA2s (iPLA2), the platelet-activating factor acetyl-
hydrolases (PAF-AH), lysosomal PLA2s, and a recently 
identified adipose-specific PLA2 (Duncan et al, 2008; 
Burke and Dennis 2009a; Ramar et al, 2010). Snake 
venom is one of the most abundant sources of secretory 
PLA2 (sPLA2), which are one of the potent molecules 
in snake venoms (Ritonja and Gubensek, 1985; Maung-
Maung et al, 1995; Chakrabarty et al, 2000). sPLA2 are 
low molecular weight proteins with molecular masses 
ranging from 13-19 kDa and generally requires Ca2+ for 
their activities (Kini, 1997; Valentin and Lambeau, 2000). 
Snake venom sPLA2 are secreted enzymes belonging to 
only two groups that are based on their primary struc-
ture and disulfide bridge pattern (Six and Dennis, 2000; 
  Rouault et al, 2003; Ramar et al, 2010). Those of group 
I are the same as pancreatic sPLA2 present in mammals 
and are found in venom of Elapidae snakes, while group 
II PLA2s belong to the Viperidae and are similar to mam-
mals’   nonpancreatic, inflammatory sPLA2s (Lambeau and 
Lazdunski, 1999; Dennis, 2000). Despite a high iden-
tity of their amino acid sequences, they exhibit distinct 
pharmacological effects including pre- or post-synaptic 
neurotoxicity,   myonecrosis, cardiotoxicity, anticoagulant, 
antiplatelet aggregation, hemorrhagic, hemolytic, and 
cytolytic activities (Kini and Evans, 1988; Kasturi and 
Gowda, 1989; Stefansson et al, 1989; Maung Maung et al, 
1995; Huang et al, 1997; Kole et al., 2000; Chakrabarty et 
al, 2002; Dong et al., 2003; Kini, 2003). Recently, acidic 
PLA2s, basic PLA2s, and synthetic peptides derived from 
PLA2 homologues have been shown to possess antitu-
mor and anti-angiogenic properties (Roberto et al, 2004; 
Araya and Lomonte, 2007; Maity et al, 2007; Bazaa et al, 
2009; Zouari-Kessentini et al, 2009; Bazaa et al, 2010; 
  Kessentini-Zouari et al, 2010).43
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salt gradient. The collection required 60min at a flow rate 
of 1ml/min. Each fraction was tested for indirect hemolytic 
activity, cytotoxicity, and inhibition of cell migration. Frac-
tion 8.3 (Drs-PLA2) had indirect hemolytic, cytotoxic, and 
cell migration inhibition activities. The molecular weight 
and purity of Drs-PLA2 were determined by SDS-PAGE and 
verified by mass spectrometry.
Sodium dodecyl sulfate-polyacrylamide gel electropho-
resis (SDS-PAGE)
Each fraction was applied to NuPAGE® Novex 4-12% 
(w/v) SDS-PAGE gels (InvitrogenTM). A XCell SureLockTM 
  system with MOPS SDS running buffer (20x) diluted to 1x 
at 200V for 50min using a Bio-Rad PowerPac Basic system 
(Bio-Rad Laboratories, CA, USA). SeeBlue Plus2 markers 
ranging from 6-191kDa were used as standards. The gel was 
stained with RapidStain (InvitrogenTM, CA, USA).
Mass spectrometry (MALDI-TOF-TOF)
Drs-PLA2 was desalted using C18 Zip-tips (Millipore 
ZTC18S096). A 1μl of 2, 5- dihydroxybenzoic acid matrix 
was spotted on a MALDI Plate and 0.5μl of desalted 
  fraction 8.3 was added onto the matrix. MALDI-TOF anal-
ysis was performed using a Bruker AUTOFLEX   II-TOF 
(Bruker   Daltonics) Mass spectrometer in positive mode. 
A Peptide Standard 2 (Bruker Daltonics) including insu-
lin-5735.89, ubiquitin-8573.6, cytochrom-12370.83, myoglo-
bin-16948.86, cytochrome-6183.08, and myoglobin-8459.67 
was performed in a reflectron mode.
N-terminal sequencing
Drs-PLA2 (0.3mg/ml) was transferred from an SDS-
PAGE onto a PVDF membrane (Milipore Immobion-
P#PVH00010) using a Semi-Dry Transblot Cell (Bio-Rad) 
at 100mV for 1hr. The membrane was stained with Coomas-
sie R-250 stain for 5min. The sample membrane was sent 
to the Iowa State University for N-terminal amino acid 
sequencing.
Anticoagulant activity
The anticoagulant activity of crude venom, fraction 8 
from size exclusion purification, and Drs-PLA2 from anion 
exchange purification were measured using the Sonoclot 
analyzer by a modification of the procedure of Sánchez et 
al (2010). Briefly, a cuvette containing glass beads as the 
clotting activator was placed into the cuvette holder which 
maintained the temperature at 37oC. A pre-warmed 13μl of 
0.25M CaCl2 were added to one side of the cuvette. A 10μl 
of Drs-PLA2 at the concentration of 0.3mg/ml (24μM) was 
added to the opposite side of the cuvette. A constant volume 
of 360μl of normal 10% (v/v) citrated human whole blood 
was added to the cuvette. The activated clot time (ACT) and 
clot rate (CR) were measured and the data were analyzed 
from Signature Viewer, software provided by Sienco, Inc. on 
an iMAC computer and analyzed by Microsoft Excel 2007. 
The negative control consisted of whole blood incubated 
with 0.02M Tris-HCl, pH 8.0 and 0.25M CaCl2.
Several studies have demonstrated that PLA2s inhibit blood 
coagulation by binding to FXa, which is the target protein 
in the coagulation cascade (Stefansson, 1990; Kerns et al, 
1999; Kini, 2005). To test whether Drs-PLA2 specifically 
inhibits factor Xa, anticoagulation was assayed utilizing 
The Russell’s viper (Daboia species) is a common venom-
ous Viperinae snake, usually found in many South Asian 
countries. The subspecies found in Thailand is Daboia 
russelli siamensis, which is also discovered in Myanmar, 
Cambodia, southern China, Taiwan, and Indonesia (Warrell, 
1989). The key lethal component of D. r. siamensis venom is 
the phospholipase A2, Daboiatoxin, which produces neuro-
toxicity in mice and exhibits oedema-inducing and myone-
crotic activities (PLA2, EC 3.1.1.4) (Ritonja and Gubensek, 
1985; Maung-Maung et al, 1995; Risch et al, 2009). PLA2 
is a multifunctional enzyme that specifically catalyzes the 
hydrolysis of the fatty acid ester bond at the position 2 of 
1,2-diacyl-sn-3-phosphoglycerides to produce free fatty 
acids and lysophospholipids (Kini, 2003; Burke and   Dennis, 
2009b).
In this study, we reported the purification and inhibitory 
activities of a PLA2 from D. r. siamensis venom. The Drs-
PLA2 displayed a cytotoxic effect and inhibited cell migra-
tion in human skin melanoma cells (SK-MEL-28). It also 
reduced tumor lung colonization of B16F10 melanoma cells 
in BALB/c mice.
MATERIALS AND METHODS
Venom collection
Daboia russelli siamensis venom was obtained from the 
Queen Saovabha Memorial Institute (QSMI, Thai Red Cross 
Society, Bangkok) and was pooled venom from an under-
determined number of snakes. The venom was extracted 
by allowing the snake to bite into a container covered with 
parafilm. The venom was centrifuged at 9,000xg for 15min 
at 4ºC and frozen at -20ºC until lyophilized. The lyophilized 
venom was stored at -20ºC until used.
Purification of Drs-PLA2
Five milligrams of lyophilized crude D. r. siamensis venom 
was suspended in 0.2ml of 0.05M ammonium acetate buffer, 
pH 8.2 and filtered through a 0.45micron filter. A total 
of 200μl (25mg/ml) was injected into a Waters 300SW 
 (PROTEIN-PAKTM, 7.5x300mm) size-exclusion column. 
The column was previously equilibrated with the elution 
buffer (0.05M ammonium acetate buffer, pH 8.2). The 
  collection process required 60min at a flow rate of 0.5ml/
min. A Waters 2487 Dual λ absorbance detector was used to 
monitor absorbencies at 280nm. Waters™ Breeze software 
was used to control the pumps and store data. Each fraction 
was screened for indirect hemolytic activity,   cytotoxicity, 
and inhibition of cell migration. Fraction 8 had a major pro-
tein band at about 14kDa with indirect hemolytic, cytotoxic, 
and cell migration inhibition activities (Figure 1). Fraction 
8 was lyophilized and further purified by a DEAE anion 
exchange HPLC column.
A Waters™ DEAE anion exchange HPLC column was used 
for the second purification step. Fraction 8 from the first 
purification step was suspended in 0.02M Tris-HCl buffer, 
pH 8.0 and further purified. Two hundred microliters of clear 
supernatant at a concentration of 11.4mg/ml were applied 
into a Waters DEAE (PROTEIN-PAKTM 5PW, 7.5x75mm) 
anion exchange column, which was previously equilibrated 
with 0.02M Tris-HCl buffer, pH 8.0. The fractions were 
eluted using 0.02M Tris-HCl, pH 8.0 with a 0-0.5M NaCl 44
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Figure 1.  Purification of Drs-PLA2. A. Size exclusion (SE) chromatographic profile of crude D. r. siamensis venom. The grey-shaded 
areas indicate the location of PLA2 activities using cytotoxicity and cell migration assays. B. SDS-PAGE analysis of venom fractions 
from SE HPLC column. Crude venom or venom fractions were run on 4-12% (w/v) bis-Tris Gel under non-reducing conditions at 
200V for 50min. The gel was stained with RapidStain. Lane 1: SeeBlue Plus2 Markers (InvitrogenTM); lane 2: crude venom (7μg); 
lanes 3-10: fractions 2-9 (7μg). C. DEAE anion exchange HPLC profile of fraction 8 from the SE HPLC column. The grey-shade 
areas indicate the location of PLA2 activities using indirect hemolytic, cytotoxicity, and cell migration assays. D. SDS-PAGE analysis 
of venom fractions from DEAE HPLC column. Crude and venom fractions from DEAE HPLC column were run on a 4-12% (w/v) 
bis-Tris gel under non-reducing conditions at 200V for 50min. The gel was stained with RapidStain for 1hr and distained overnight 
with 18megaohm water. Lane 1: SeeBlue Plus2 Markers (InvitrogenTM); lane 2: crude venom (7μg); lane 3: fraction 8 from SE (7μg); 
lane 4: fraction 8.1 (1.4μg); lane 5: fraction 8.2 (1.2μg); lane 6: fraction 8.3 (6μg); lane 7: fraction 8.4 (1.6μg); lane 8: fraction 8.5 
(1.4μg); lane 9: fraction 8.6 (2μg); lane 10: fraction 8.7 (1.2μg); lane 11: fraction 8.8 (1.6μg); lane 12: fraction 8.9 (1.4μg); lane13: 
fraction 8.10 (1 μg). E. SDS-PAGE analysis of fraction 8 and 8.3 (Drs-PLA2). Drs-PLA2 was run on 4-12% (w/v) bis-Tris Gel under 
reducing conditions. Lane 1: SeeBlue Plus2 Markers (InvitrogenTM); lane 2: reduced form of fraction 8 from SE (7μg); lane 3: reduced 
form of Drs-PLA2 (3μg). F. Mass spectrometry analysis of Drs-PLA2.45
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various concentrations and incubation times. SK-MEL-28 
cells were the most sensitive, and were further used for the 
determination of the cytotoxic and cell migration inhibi-
tion activities of venom fractions.
Each fraction collected from HPLC (100μg/ml), or 
 Drs-PLA2 at various concentrations was added to 
  SK-MEL-28 cell suspension at 37oC for 72hr. Then, 10μl 
of MTT (5mg/ml) was added to each well. After incubation 
for 4hr at 37oC, MTT was aspirated and 150μl of DMSO 
was added to lyse the cells. The absorbance at 570nm was 
read using a Beckman CoulterTM model AD 340 reader. 
Doxorubicin (5μg/ml), an anticancer drug was used as the 
positive control. The negative control was cells treated with 
0.02M Tris-HCl, pH 8.0. The percentage of cell viability 
was calculated relative to the negative control, which was 
defined as 100%. The 50% cytotoxic concentration (CC50) 
of sample is defined as the protein concentration generating 
cell viability of 50%. The values of the percentages of cell 
viability were plotted against venom concentrations, and 
the CC50 was determined. Experiments were performed in 
triplicate.
Cell migration assays of the Drs-PLA2
Cell migration inhibition was determined by a wound-
healing assay according to the procedure of Galán et al 
(2008). Briefly, SK-MEL-28 cells were plated (5x105 cells/
ml) on a 24-well plate. After 24hr, the confluent monolayer 
was scratched with a sterile pipette tip creating the scratch 
wound of 16-23mm width. The detached cells were washed 
away and renewed with 0.9ml of EMEM mixed with crude 
venom at various concentrations, venom fractions col-
lected from HPLC (6.25μg/ml), or Drs-PLA2 at various 
  concentrations. The cells were then incubated at 37oC in a 
CO2 incubator for 0, 3, 6, 12, 24, and 48hr. After the incuba-
tion period, cell migration was observed under an inverted 
microscope (ULWCD 0.3 Olympus CK2, Japan). Echistatin 
(10μg/ml), a disintegrin known to inhibit SK-MEL-28 cell 
migration was used as the positive control (Sánchez et al, 
2009). The negative control was cells treated with 0.02 M 
Tris-HCl, pH 8.0. The percentage of cell migration inhi-
bition was calculated by the following equation: [(C-E)/C] 
x100, where C is the distance of the wound scratch (mm) at 
zero time of the negative control, and E is the distance of 
the wound scratch (mm) at the final incubation time for the 
venom. The 50% inhibitory concentration (IC50) is defined 
as the protein concentration that inhibits cell migration 
by 50%. The values of the percentages of cell migration 
inhibition were plotted against protein concentrations, and 
the IC50 was determined. Experiments were performed in 
 triplicate.
Inhibition of lung tumor colonization in vivo
B16F10 murine skin melanoma cells (106cells) were mixed 
with Drs-PLA2 at the concentration of 100μg/kg body 
weight and then incubated at 37oC for 1hr. A 200μl of the 
sample mixture was injected into the tail veins of 18-20gm 
BALB/c mice. After 19 days, the mice were sacrificed to 
detect tumors in the lungs. Mice injected with only B16F10 
cells were used as the positive control group. Mice injected 
with only Dulbecco’s modified Eagle’s medium were used 
as the negative control group. The tumors were counted and 
compared to the positive control group.
FX deficient plasma by a method of Suntravat et al (2010). 
Briefly, 300μl of FX deficient plasma were added to a 
cuvette without glass beads (Sienco, Inc, USA). Coagula-
tion was activated by the addition of 10μl of pre-warmed 
0.30M CaCl2 and 10μl of 6nM FXa pre-incubated at 37oC 
for 30min with 10μl of 0.1mg/ml (8μM) of Drs-PLA2. The 
controls included FX deficient plasma, 0.30M CaCl2 and 
3nM FXa without Drs-PLA2 (positive control), and FX 
deficient plasma, 0.30M CaCl2 without 3nM FXa (negative 
control).
Indirect hemolytic assay
The crude venom and fractions were tested for PLA2 activ-
ity. The hemolysis indirect was tested on human washed 
red blood cells (1.2%, v/v) agarose plates (0.8%, w/v) with 
calcium chloride (0.01M-1%, v/v). The egg yolk solution 
was added to the agarose medium at a final concentra-
tion of 1.2% (v/v). Three millimeters diameter wells were 
made into the agarose plates. Twenty-five microlitres of 
D. r.   siamensis and Crotalus atrox crude venoms were tested 
as positive hemolytic controls at a concentration of 1mg/
ml. Fractions 8 (Figure 1A) and 8.3 (Figure 1C) were tested 
at a concentration of 0.5 and 0.3mg/ml, respectively. PBS 
was used as a negative hemolytic control. The plates were 
incubated at 37oC for 24hr. The specific activities were esti-
mated as the ratio between the diameter (millimeters) of the 
hemolytic halo and the amount of protein added per well 
(micrograms).
Cytotoxicity assay of crude venom and Drs-PLA2 on 
cancer cell lines
Human skin melanoma (SK-MEL-28), human urinary blad-
der carcinoma (T24), human lung bronchus carcinoma 
(ChaGo-K-1), human fibrosarcoma (HT-1080), and murine 
skin melanoma (B16F10) cell lines were obtained from 
American Type Tissue Culture Collection (ATCC). The 
SK-MEL-28 and HT-1080 cell lines were maintained with 
Eagle’s minimum essential medium (EMEM) containing 
10% (v/v) fetal bovine serum (FBS), 50U/ml penicillin, and 
50μg/ml streptomycin. The T24 cells were maintained with 
McCoy’s 5A minimum essential medium containing 10% 
(v/v) FBS, 50U/ml penicillin, and 50μg/ml streptomycin. 
The B16F10 cells were maintained with Dulbecco’s modi-
fied Eagle’s medium containing 10% (v/v) FBS, 50U/ml 
penicillin, and 50μg/ml streptomycin. The ChaGo-K-1 cells 
were maintained with RPMI 1640 medium supplemented 
containing 10% (v/v) FBS, 0.02M sodium bicarbonate, 
100U/ml penicillin, and 100μg/ml streptomycin. The cul-
tured medium was replaced daily. Cells were incubated at 
37oC in a 5% (v/v) CO2 humidified incubator.
Cytotoxic activity of D. r. siamensis venom (1mg ml) 
was performed according to the procedure of Umthong 
et al (2009) by measuring cell viability using MTT 
(3-(4, 5-Dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium 
bromide). To identify the most sensitive cancer cell lines 
for further screening cytotoxic and cell migration inhi-
bition activities of venom fractions, cytotoxic activity 
of crude venom was determined on SK-MEL-28, T24, 
ChaGo-K-1, and HT-1080 cells. Cells were cultured on 
96-wells flat-bottom microtiter plates at ∼105 cells/well 
in triplicate and incubated at 37oC in 5% (v/v) CO2 for 
24hr. Crude venom was added to each cell suspension at 46
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Sodium dodecyl sulfate-polyacrylamide gel electropho-
resis (SDS-PAGE)
Fractions from all chromatographic fractionation were 
applied to NuPAGE® Novex 4-12% (w/v) Bis-Tris SDS-
PAGE gels. Drs-PLA2 showed a single band at about 14kDa 
using SDS-PAGE under non-reducing and reducing condi-
tions (Figure 1D, lane 6 and 1E, lane 3). These results sug-
gest that Drs-PLA2 is a purified monomeric protein. The 
monomeric Drs-PLA2 is similar to the PLA2 isolated from 
Cerastes cerastes venom (Zouari-Kessentini et al, 2009).
Mass spectrometry (MALDI-TOF-TOF)
Mass analysis was performed on Drs-PLA2 using a Bruker 
AUTOFLEX II-TOF (Bruker Daltonics) resulting with a 
mass of 13,679Da, which falls in the range of many venom 
PLA2s (Figure 1F).
N-terminal sequencing
The N-terminal amino acid sequencing of Drs-PLA2 was 
NLFQFARMINGKLGAFSV displaying 100% sequence 
homology with basic PLA2s (Table 1). In addition, it is very 
similar (95% identity) to other basic PLA2s from viperid 
species (Table 1).
Anticoagulant activity
Crude venom, fraction 8, and the Drs-PLA2 were exam-
ined for coagulant activity using the Sonoclot analyzer. 
The Sonoclot signatures of crude venom, fraction 8, and 
Statistical analysis
All results were expressed as mean ± standard deviation 
(SD). Their significance was analyzed by the Student’s 
t-test. The level of significance was at P <0.05.
RESULTS
Purification of Drs-PLA2
Crude venom was fractionated by size exclusion chroma-
tography and nine fractions were collected (Figure 1A). 
The high molecular weight proteins (97kDa) were observed 
in fractions 2, 3, and 4. Low molecular weight proteins at 
molecular weights of about 14 and 6kDa were found in frac-
tions 4 through 9. Fractions 2 through 9 were screened for 
cytotoxic and migration inhibition activities using the most 
sensitive cell towards the cytotoxic action of crude D. r. sia-
mensis venom. Fraction 8 showed the most intense protein 
band at about 14kDa (Figure 1B, lane 9). Fraction 8 had the 
highest cytotoxicity with a CC50 of 1.47μg/ml, the migra-
tion inhibition activity with an IC50 of 1.22μg/ml, and the 
indirect hemolytic activity (data not shown). Fraction 8 was 
further purified by anion exchange HPLC chromatogra-
phy. Ten different fractions were collected (Figure 1C). The 
molecular weight of fraction 8.3 was verified by mass spec-
trometry (13,679Da) (Figure 1F). The characteristics of the 
crude venom, fractions 8 and Drs-PLA2 used in this study 
are shown in Table 1.
Table 1.  Comparison of N-terminal sequence homology between Drs-PLA2 and other snake venom PLA2s.
Snake PLA2 Accession 
No. or Ref.
Organism N-terminal sequence Identity (%)
Drs-PLA2* - D. r. siamensis NLFQFARMINGKLGAFSV† -
Basic PLA2 AAZ53185 D. r. limitis NLFQFARMINGKLGAFSV 100
Rv4RV7 (basic PLA2) 1OQS Vipera russelli formosensis NLFQFARMINGKLGAFSV 100
Viperotoxin (basic PLA2) Q02471.1 D. r. siamensis NLFQFARMINGKLGAFSV 100
Basic PLA2 2I0U V . nikolskii NLFQFAKMINGKLGAFSV 95
Vaspin basic subunit CAE47300 V . aspis zinnikeri NLFQFAKMINGKLGAFSV 95
Basic PLA2 (B chain) Q8JFG0 V . a. aspis NLFQFAKMINGKLGAFSV 95
Vipoxin complex 1AOK V . ammodytes meridionalis NLFQFAKMINGKLGAFSV 95
Basic PLA2 I B60512 V . aspis NLFQFALMINGKLGAFSV 95
Vaspin basic subunit CAE47291.1 V . a. aspis NLFQLAKMINGKLGAFSV 89
Vaspin B isoform 1 AAO86503.1 V . a. aspis NLFQSAKMINGKLGAFSV 89
Basic PLA2-II ABD24037.1 D. r. russellii NLFQFARMIDAKQEAFS 77
Basic PLA2 AAZ53178.1 D. r. siamensis NLFQFARLIDAKQEAFS 71
Basic PLA2 AAP37177.1 D. r. siamensis NLFQFARLIDAKQEAFS 71
Acidic PLA2 ACD43469 D. r. siamensis NLFQFGDMINKKTGRFGL 61
Acid Daboiatoxin (DbTx) 1 D. r. siamensis NFFQFAEMIVKMTGKEAV 50
Acidic PLA2 2 Cerastes cerastes NLYQFGKMIKHKTGKSAL 44
Acidic PLA2 AAP41217.1 Echis carinatus NLYQFGRMIWNRTGKL 43
*This work
†The sequences were aligned using BLASTP 2.2.25 program of GenBank.
1 Maung-Maung et al., 1995; Risch et al., 2009; Ritonja and Gubensek, 1985
2 Zouari-Kessentini et al., 2009
Bold letter indicates different residues as compared to Drs-PLA2.47
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Effects of crude venom at the various concentrations (6.25, 
12.5, 25, 50, and 100μg/ml) and various incubation times on 
SK-MEL-28 cell viability were determined. Crude venom 
reduced cell viability in a dose-dependent manner. Crude 
venom at the concentration of 100μg/ml showed the low-
est cell viability (20%) at 24hr and slightly decreased in 
the percentage of cell viability at 48hr and 72hr (data not 
shown).
Cytotoxicity and cell migration assays of the Drs-PLA2
Purified Drs-PLA2 decreased SK-MEL-28 percent cell 
  viability in a dose-dependent manner (0.012μg/ml-98% 
±10; 0.060μg/ml-94% ±5; 0.30μg/ml-80% ±3; 1.5μg/
ml-40% ±10; and 7.5 μg/ml-20% ±5). The cytotoxic activ-
ity of the PLA2 was compared to crude venom. The CC50 
value of the Drs-PLA2 (0.90μg/ml) was approximately 6 
times less than the CC50 value of crude venom (5.63μg/
ml). In addition, the Drs-PLA2 inhibited the migration 
of   SK-MEL-28 with an IC50 of 0.35μg/ml, which was 
11.3x lower than crude venom (3.97 μg/ml). Effects of 
the Drs-PLA2 at various incubation times on cell migra-
tion inhibition were determined. The percent inhibition of 
SK-MEL-28 cell migration of echistatin (positive control) 
at 3-12hr showed no significant difference to the percent 
inhibition of the Drs-PLA2. Subsequently, similar inhibi-
tion activity was found at 24hr. After a 48hr incubation 
period, cell migration inhibition activity of the Drs-PLA2 
was higher than the positive control (Figure 3A). The 
actual images of SK-MEL-28 cell migration with the Drs-
PLA2 at 24hr are shown in Figure 3B.
Inhibition of lung tumor colonization in vivo
The Drs-PLA2 was further tested for anti-metastatic prop-
erty using an in vivo skin melanoma cell colonization assay. 
The Drs-PLA2 significantly reduced tumor nodules by 
∼65% compared with the positive control group (Table 2; 
Figure 4).
DISCUSSION
Heart attack, stroke, and cancers are among the most seri-
ous medical problems worldwide. Venomous snakes con-
tain an array of molecules with many different biological 
the Drs-PLA2 are shown in Figure 2. Crude D. r. siamen-
sis venom known to have the coagulant activity signifi-
cantly shortened ACT (0.32±0.03min) and increased the 
CR (86.50±7.78U). Fraction 8 has the signature of coagu-
lant activity with a shortened the ACT (0.66±0.03min) and 
enhanced the CR (44.00±5.66U). In contrast, the Drs-PLA2 
had a signature of anticoagulant activity with an extended 
ACT (3.88±0.78min) and slower CR (5.60±0.36U). The 
positive blood control incubated with 0.02M Tris, pH 8.0 
buffer had an average ACT of 3.46±0.30min, and a CR of 
15.10±2.72U.
To identify FXa as a target protein of Drs-PLA2, we dem-
onstrated that Drs-PLA2 significantly prolonged the ACT 
(3.21±0.11min) and lowered the CR (1.70±0.28U). The 
positive control had an average ACT of 2.73±0.22 min and 
a CR of 3.37±0.91 U.
Indirect hemolytic assay
All samples displayed indirect hemolytic activity with Drs-
PLA2 having the highest specific activity of 2mm/μg±0.2 
followed by fraction 8 at 1.4mm/μg ±0.1. D. r. siamensis 
and C. atrox crude venoms had specific activities of 0.8±0.1 
and 1.0mm/μg ±0.2, respectively.
Cytotoxicity assay of crude venom on cancer cell lines
Four different cell lines (SK-MEL-28, T24, ChaGo-K-1, 
and HT-1080 cells) were treated with a 100μg/ml of crude 
D. r. siamensis venom. The SK-MEL-28 cell line was the 
most sensitive (15-20% cell viability) to crude venom at 
all three incubation times (data not shown). All other cell 
lines exhibited 50-60% cell viability (data not shown). Thus, 
SK-MEL-28 cells were further used for the determination 
of cytotoxic and cell migration inhibition activities of the 
venom fractions.
Figure 2.  Whole Blood Sonoclot Signatures of D. r. siamensis 
venom and venom fractions. Data from the Sonoclot Signatures 
further analyzed by Microsoft Excel 2007 obtained when human 
citrated whole blood was activated by crude venom, fraction 8 
from size exclusion purification, and Drs-PLA2. The ACT is the 
time (min) in which whole blood begins to clot. The CR is defined 
as the rate of fibrin polymerization, which is the slope in the lin-
ear part of the curves and is defined as the change clot signal with 
change in time (U = Δsignal/Δtime). The solid line represents the 
ACT. The dashed line represents the CR.
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Table 2.  Comparative analysis of tumor foci per lung in BALB/c 
mice using purified Drs-PLA2 compared to controls
Control Drs-PLA2  
(100 μg/kg)
Mice no. 13 19
Minimum tumors 21 0
Maximum tumors 90 40
Mean tumors 49.15 17.42
Standard deviation 24.54 13.91
Tumor inhibition (%)a - 64.50 
P valueb - 0.0002
a    The percent tumor inhibition was calculated by the following 
equation: [(E/C) x 100]-100, where E is the mean tumors of the 
Drs-PLA2 group, and C is the mean tumors of the control group.
b   P value as compared to the control. The level of significance was 
at P < 0.05.48
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Figure 3.  Inhibition of Cell Migration by Drs-PLA2. A. Cell migration inhibition activity of the Drs-PLA2 on SK-MEL-28 cells using 
a wound- healing assay. Cell migration inhibition was evaluated by incubating 5x105 cells with Drs-PLA2 (6μg/ml) for 3, 6, 12, 24, 
or 48hr incubation periods. Echistatin (10μg/ml) was used as the positive control. The negative control consisted of cells treated with 
0.02M Tris-HCl, pH 8.0. The results are expressed as the percentage of cell migration inhibition with respect to activity of the nega-
tive control, and as mean ±SD (n=3). B. SK-MEL-28 cells with the Drs-PLA2 (1.2μg/ml) at 24hr. (1) SK-MEL-28 cells were treated 
with 0.02M Tris-HCl, pH 8.0 at 24hr. (2) SK-MEL-28 cells were treated with Drs-PLA2 at 0hr, (3) 12hr, and (4) 24hr.
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Figure 4.  Inhibition of Lung Tumor Colonization by Drs-PLA2. The effect of the Drs-PLA2 on B16F10 lung tumor colonization in 
BALB/c mice at 100μg/kg mouse. The B16F10 cells (2x105) were injected in the lateral tail vein in the absence or presence of the 
Drs-PLA2. The lungs were isolated from the mice 19-days post-injections and observed for tumor colonization. A. Medium-treated 
mice (control); B. B16F10 cells in medium; C. 100μg of the Drs-PLA2/kg mouse.
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crude venom had a higher cytotoxic activity on SK-MEL-28 
cells than T24, HT-1080, and ChaGo-K-1 (data not shown). 
In addition, the PLA2 inhibited migration of SK-MEL-28 
cells (Figure 3A and 3B). Although, there are studies dem-
onstrating the anti-tumor activity of PLA2s in vitro, to the 
best of our knowledge, with the exception of the study by 
Maity et al (2007), there is insufficient in vivo evidence of 
the effects of secreted PLA2s on tumors. To confirm the 
metastasis property in our study, we determined the inhi-
bition of skin melanoma cell colonization by Drs-PLA2, in 
vivo. It was observed that the pretreatment of B16F10 mela-
noma cells with the Drs-PLA2 inhibited growth of tumors in 
BALB/c mice by ∼65%.
Phospholipases A2s are enzymes that spark interest in 
the medical field because of their participation in a large 
number of human inflammatory diseases (Rodrigues et al, 
2009). The activity and expression of several PLA2 isoforms 
are augmented in numerous human cancers, signifying that 
these enzymes have a vital role in both tumor development 
and progression and can be targets for anti-cancer drugs. On 
the other hand, some PLA2s isolated from Viperidae ven-
oms are capable of inducing antitumoral activity (Rodrigues 
et al, 2009), suggesting that these molecules can be a new 
class of anticancer agents and provide new molecular and 
biological insights of cancer development. Furthermore, the 
initiation of the coagulation system in cancer patients is a 
well-known phenomenon accountable for recurrent throm-
bosis, which is the second most common cause of death in 
cancer patients (Xie et al, 2005). Thromboembolic com-
plications consist of a wide range of clinical tribulations, 
from pulmonary embolism and deep venous thrombosis to 
superficial thrombophlebitis and clotting of central venous 
catheters (Versteeg et al, 2004; Xie et al, 2005; Furie and 
Furie, 2006).
CONCLUSIONS
In this study, we report for the first time a PLA2 purified 
from Thailand D. r. siamensis venom that had cytotoxic, 
anticoagulant, and antitumor activity, in vivo and in vitro. 
With the increase in protein engineering, it is now possible 
to produce a smaller fragment of this molecule that could 
preserve or improve its anticoagulant and antitumor activi-
ties, which could be useful in medical applications.
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activities, which could have beneficial applications in med-
icine and biomedical research. In this study, we reported 
the purification and characterization of Drs-PLA2 isolated 
from crude D. r. siamensis venom. The Drs-PLA2 (13,679 
Da) was purified from crude venom by a two-step purifica-
tion procedure (Figure 1A, 1B and 1C) with approximately 
27.4% yield (data not shown). The N-terminal sequence (18 
amino acids) showed 100% homology to basic PLA2s from 
the viperid snakes (Table 1). However, it should be noted 
that this homology is based on the comparison of amino 
acid sequences at the N-terminal region of the molecules, 
without taking into account the remaining sequence of our 
PLA2. A basic PLA2 has been identified in the venom of 
D. r. siamensis (viperotoxin) sharing 100% N-terminus 
sequence homology with Drs-PLA2 (Table 1); however, 
viperotoxin is a basic protein with an approximate pI of 
8.96. The pI for Drs-PLA2 appears to be slightly acidic 
since it bound to the anion exchange column, but was easily 
eluted with slightly above a 10% (w/v) NaCl (0.5M) solu-
tion (Figure 1C). These results suggest that viperotoxin is 
different from Drs-PLA2.
Although many PLA2s exhibit a high degree of similarity in 
their amino acid sequences, they display different biological 
effects. Tsai et al (2007) reported that PLA2s isolated from 
Myanmar Russell’s viper venom (D. r. siamensis) and East-
ern India Russell’s viper (D. russelli) venom share 97-100% 
amino acid sequence identity, but they differ in their enzy-
matic and lethality effects.
Previous studies have indicated that several PLA2s iso-
lated from the families Crotalidae, Viperidae, and Elapi-
dae possessed anticoagulant properties (Mukherjee, 2007; 
Pereanez et al, 2009; Garcia Denegri et al, 2010). In this 
study, based on the ACT and CR data, fraction 8 from size 
exclusion purification exhibited a coagulant signature with 
a shortened ACT and an increased CR (Figure 2). In con-
trast, the Drs-PLA2 from the anion exchange purification 
had an anticoagulant activity with an extended ACT and a 
decreased CR. These results indicated that low molecular 
weight procoagulant molecules were completely removed 
from the first purification step (Figure 1E). Since most snake 
venoms contain PLA2 isoforms, it would be important to 
purify PLA2s from venom of individual snakes. In addition, 
the Drs-PLA2 had an anticoagulation effect on FX deficient 
plasma by inhibiting FXa, which is the target protein for 
anticoagulant PLA2s as previously reported (Stefansson, 
1990; Kerns et al, 1999).
In recent studies, cytotoxicity, inhibition of cell migration, 
and tumor metastasis properties of PLA2s have been widely 
investigated. For example, a basic PLA2, RVV-7 (7.2kDa) 
isolated from D. r. russellii venom had strong cytotoxic 
activity on B16F10 melanoma cells. It also inhibited tumor 
growth in BLJ6 mice (Maity et al, 2007). Furthermore, an 
acidic Asp49 PLA2 (13,626.64Da) isolated from Macrovi-
pera lebetina transmediterranea venom completely inhib-
ited cell adhesion and migration of various human tumor 
cells mediated by α5β1 and αv integrins, but lacked cyto-
toxicity (Bazaa et al, 2009). Two acidic PLA2s purified from 
Cerastes cerastes venom, CC-PLA2-1 and CC-PLA2-2, 
inhibited HT-1080 cell migration towards fibrinogen and 
fibronectin (Zouari-Kessentini et al, 2009). In our study, 50
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